Erick Lucera Biography and Net Worth

Director of Beyond Air


Erick Lucera joined Beyond Air’s Board of Directors in August 2017. He was appointed Chief Financial Officer for AVEO Oncology, a NASDAQ traded biopharmaceutical company focused on targeted medicines for oncology and other unmet medical needs, in 2020. Mr. Lucera was most recently Chief Finanical Officer of Valeritas, a commercial-stage company developing new technology for diabetes. Prior to that, Mr. Lucera served as Chief Financial Officer, Treasurer, and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company’s product pipeline through a series of acquisitions and in-licensing transactions financed through 5 public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital, and head of the healthcare research team at Independence Investments. He holds a CPH from Harvard University, a Master of Science in Quantitative Finance from Boston College, an MBA from Indiana University Bloomington, and a Bachelor of Science in Accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.

What is Erick Lucera's net worth?

The estimated net worth of Erick Lucera is at least $2.79 thousand as of August 14th, 2024. Mr. Lucera owns 2,180 shares of Beyond Air stock worth more than $2,790 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Lucera may own. Learn More about Erick Lucera's net worth.

How do I contact Erick Lucera?

The corporate mailing address for Mr. Lucera and other Beyond Air executives is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. Beyond Air can also be reached via phone at (516) 665-8200 and via email at [email protected]. Learn More on Erick Lucera's contact information.

Has Erick Lucera been buying or selling shares of Beyond Air?

Erick Lucera has not been actively trading shares of Beyond Air over the course of the past ninety days. Most recently, on Wednesday, August 14th, Erick Lucera bought 1,963 shares of Beyond Air stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $15,704.00. Following the completion of the transaction, the director now directly owns 2,180 shares of the company's stock, valued at $17,440. Learn More on Erick Lucera's trading history.

Who are Beyond Air's active insiders?

Beyond Air's insider roster includes Amir Avniel (COO), Douglas Beck (CFO), Ron Bentsur (Director), Robert Carey (Director), Michael Gaul (COO), Steven Lisi (CEO), and Erick Lucera (Director). Learn More on Beyond Air's active insiders.

Are insiders buying or selling shares of Beyond Air?

In the last year, Beyond Air insiders bought shares 2 times. They purchased a total of 50,300 shares worth more than $252,280.00. The most recent insider tranaction occured on March, 14th when Director Robert Carey bought 50,000 shares worth more than $250,000.00. Insiders at Beyond Air own 19.4% of the company. Learn More about insider trades at Beyond Air.

Information on this page was last updated on 3/14/2025.

Erick Lucera Insider Trading History at Beyond Air

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/14/2024Buy1,963$8.00$15,704.002,180View SEC Filing Icon  
3/16/2023Buy100$136.40$13,640.00217View SEC Filing Icon  
See Full Table

Erick Lucera Buying and Selling Activity at Beyond Air

This chart shows Erick Lucera's buying and selling at Beyond Air by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beyond Air Company Overview

Beyond Air logo
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Read More

Today's Range

Now: $1.28
Low: $1.10
High: $1.30

50 Day Range

MA: $1.92
Low: $1.09
High: $2.70

2 Week Range

Now: $1.28
Low: $1.00
High: $11.20

Volume

144,527 shs

Average Volume

179,162 shs

Market Capitalization

$10.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3